Natco Pharma acquires 40 million shares in eGenesis Inc
The city-based drug maker in a statement said the eGenesis Genome Engineering and Production platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.
Natco Pharma Ltd on Wednesday said its Canadian subsidiary acquired 40 million shares in eGenesis Inc., a biotechnology company at the forefront of xenotransplantation focused on developing safe and effective human compatible organs for transplant, for USD 8 million.
The city-based drug maker in a statement said the eGenesis Genome Engineering and Production platform is the only technology of its kind to comprehensively address cross-species molecular incompatibilities and viral risk via genetic engineering to improve the lives of patients in need of a transplant.
eGenesis is advancing development programs for kidney transplant, acute liver failure, and heart transplant, it said.
“We are excited to get involved with eGenesis, Inc. With respect to their pioneering work in xenotransplantation. We agree with the vision of eGenesis that xenotransplantation technology has the potential to end the global transplant shortage and transform the treatment of organ failure by eliminating waitlist mortality,” Rajeev Nannapaneni, Vice Chairman and CEO of Natco said.
“We are thrilled to welcome Natco as an investor. Their support will be used in advancing our research and bringing our innovative therapies to market,” said Mike Curtis, CEO of eGenesis Inc. In March 2024, eGenesis announced the world's first porcine kidney transplant in a living patient. The transplant was authorized by the U.S. Food & Drug Administration (FDA) under the Expanded Access pathway.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
SIP+SWP: Rs 15,000 monthly SIP investment for 20 years and Rs 100,000 monthly income for 45 years; know how it is possible
SBI Senior Citizen FD Rates 2024: What you can get if you invest Rs 3.5 lakh, Rs 7 lakh, Rs 10.50 lakh, and Rs 14 lakh in 1-, 3-, and 5-year FDs
15x15x15 Formula: In how many years Rs 15,000 monthly SIP can grow to over Rs 1 crore; see calculations
NPS vs OPS vs UPS: On Rs 15,000 monthly contribution for 30 years, which of 3 can give highest pension? Get calculations
03:12 PM IST